We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02141828
Recruitment Status : Completed
First Posted : May 20, 2014
Last Update Posted : May 8, 2020
Celgene Corporation
Information provided by (Responsible Party):
Epizyme, Inc.

Brief Summary:
A subset of patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) harbor rearrangements of the MLL gene, which are detected either by cytogenetic or fluorescent in situ hybridization evaluation at the time of diagnosis. A protein called DOT1L plays an important role in the malignant process in these leukemias. EPZ-5676 is a molecule that blocks the activity of DOT1L, and is therefore being evaluated in the treatment of patients with MLL-rearranged leukemias.

Condition or disease Intervention/treatment Phase
Leukemia Acute Myeloid Leukemia Acute Lymphocytic Leukemia Acute Leukemias Drug: EPZ-5676 Phase 1

Detailed Description:
This is a Phase 1b study of EPZ-5676 in pediatric patients. The study will have two phases. The first phase will assess escalating doses of EPZ-5676 in order to determine the maximally tolerated dose (MTD) or recommended phase 2 dose (RP2D) of EPZ-5676 as a 28-day continuous IV infusion. Once the MTD and/or RP2D is established, a second phase of the study will further evaluate the safety of EPZ-5676 and assess the anti-leukemia activity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Study Start Date : May 2014
Actual Primary Completion Date : May 2016
Actual Study Completion Date : June 2016

Arm Intervention/treatment
Experimental: EPZ-5676
EPZ-5676 Dose escalation and expansion cohorts
Drug: EPZ-5676
28-day continuous IV infusion of each 28-day cycle, given until disease progression or unacceptable toxicity develops.
Other Names:
  • EPZ5676
  • DOT1L

Primary Outcome Measures :
  1. Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of EPZ-5676. [ Time Frame: 12 months ]
    To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of EPZ-5676 as determined by incidence of protocol-specified dose-limiting adverse events.

  2. To assess the safety and tolerability of EPZ-5676 administered as a continuous intravenous (CIV) infusion [ Time Frame: 22 months ]
    Safety and tolerability will be assessed by the incidence of adverse events in patients treated with EPZ-5676 and the evaluation of adverse events, vital signs, physical examination, 12-lead ECG, and laboratory assessments.

Secondary Outcome Measures :
  1. Determine the pharmacokinetic (PK) and pharmacodynamic (PD) profile of EPZ-5676 [ Time Frame: 18 months ]

    The pharmacokinetic (PK) profile will include the analysis of Cmax, AUC and steady state concentration of EPZ-5676.

    The pharmacodynamic (PD) profile will assess the effects of EPZ-5676 in peripheral blood mononuclear (PBMC) and bone marrow cells.

  2. Evaluate early evidence of anti-tumor activity [ Time Frame: 18 months ]
    Anti-tumor activity will be assessed by objective response (OR) in pediatric patients

Other Outcome Measures:
  1. To determine cerebrospinal fluid (CSF) concentrations EPZ-5676 in pediatric patients receiving EPZ-5676 by CIV infusion [ Time Frame: 18 months ]
  2. Analysis of tumor cells for somatic mutations as potential predictors of response [ Time Frame: 18 months ]
    Somatic mutations to include mRNA and proteins or markers of biological pathways as potential predictors of response to EPZ-5676 treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Months to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age: >3 months to <18 years of age.
  2. Diagnosis: Patients must have documented relapsed/refractory ALL, AML, or acute leukemia of ambiguous lineage and meet the following criteria:

    • Patients must have at least received an appropriate induction therapy regimen. Patients with persistent leukemia after induction therapy, or with recurrence of leukemia at any time during the course of treatment (including allogeneic HSCT) are eligible;
    • Patients must have > 10% leukemic blasts in the bone marrow;
    • Patients must have rearrangement involving the MLL gene, including reciprocal chromosomal translocations involving 11q23 by FISH, cytogenetic analysis, polymerase chain reaction (PCR) or next-generation sequencing (NGS) OR partial tandem duplication (PTD) of MLL by PCR or NGS.
  3. Therapeutic Options: Patients must be ineligible or inappropriate for other treatment regimens known to have curative potential.
  4. Performance Level: Karnofsky > 50% for pts > 12 years; Lansky > 50% for pts < 12 years of age.
  5. Prior Therapy: Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

    Myelosuppressive Chemotherapy:

    • 14 days must have elapsed since the completion of cytotoxic therapy
    • Patients may receive hydroxyurea, low-dose cytarabine and/or glucocorticoids to control peripheral blood leukemic cell counts at study entry
    • At least 7 days since the completion of therapy with hematopoietic growth factors
    • At least 7 days since the completion of therapy with a biologic agent
    • At least 21 days since receipt of chimeric antigen receptor therapy or other modified T cell therapy
    • At least 60 days from prior total body irradiation (TBI)
    • At least 60 days must have elapsed from hematopoietic stem cell transplantation (HSCT)
  6. Renal and Hepatic Function: Patient must have adequate renal and hepatic functions as indicated by the following laboratory values:

    • Patient must have a calculated creatinine clearance or radioisotope GFR > 60mL/min/1.73m2 or a normal serum creatinine based on age/gender
    • Total bilirubin < 1.5 x ULN for age or normal conjugated bilirubin
    • ALT and AST < 3 x ULN (unless attributed to leukemic involvement)
  7. Cardiac Function: Patient must have a shortening fraction (SF) of > 27% or an ejection fraction (EF) of > 50% by echocardiogram or MUGA scan.

Exclusion Criteria:

  1. Patients with CNS 3 disease or symptomatic CNS disease
  2. Clinically active heart disease including prolonged QTc or prolonged PR interval, or history of arrhythmias
  3. On immunosuppressive or other anti-leukemic therapy, excluding patients receiving glucocorticoids for management of circulating blast count or patients on a stable dose (<20mg/m2/day prednisone or equivalent) of systemic or topical glucocorticoid therapy with ≤ Grade 1 GvHD or tapering dose of calcineurin inhibitor
  4. Patients with known bleeding diathesis or prothrombin time (PT) or aPTT >1.5 x ULN or fibrinogen <0.5 x LLN
  5. Receiving prophylactic use of hematopoietic colony stimulating factors
  6. Known history of infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBsAg positive) or hepatitis C virus (anti-HCV positive)
  7. Being actively treated for another concurrent malignancy
  8. Pregnant or nursing females;
  9. Male patients not willing to use a condom
  10. Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, significant graft-versus-host-disease (GvHD) (Grade 2-4), or psychiatric illness/social situations that would limit compliance with study requirements
  11. Patients who are concurrently receiving strong inducers/inhibitors of CYP3A
  12. Patients with known history of Trisomy 21 (Down Syndrome), history of congenital immunodeficiency or inherited marrow failure disorder.
  13. Patients with known bleeding diathesis, or PT (Prothrombin time) or aPTT (activated partial thromboplastin time) > 1.5x ULN or <0.5x LLN.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02141828

Layout table for location information
United States, California
Childrens Hospital Los Angeles
Los Angeles, California, United States, 90027
University of California San Francisco Medical Center-Parnassus
San Francisco, California, United States, 94143
United States, Colorado
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
United States, Georgia
Emory Children's Healthcare of Atlanta
Atlanta, Georgia, United States, 30322
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
Canada, Ontario
The Hospital for Sick Kids
Toronto, Ontario, Canada
Sponsors and Collaborators
Epizyme, Inc.
Celgene Corporation
Layout table for investigator information
Principal Investigator: Neal Shukla, MD Memorial Sloan Kettering Cancer Center
Principal Investigator: Lia Gore, MD Children's Hospital Colorado
Principal Investigator: Pat Brown, MD Johns Hopkins University
Principal Investigator: Lewis Silverman, MD Dana Farber
Principal Investigator: Maureen O'Brien, MD Children's Hospital Medical Center, Cincinnati
Principal Investigator: Jim A Whitlock, MD Hospital of Sick Kids
Principal Investigator: Cynthia Wetmore, MD PhD Emory Children's Healthcare of Atlanta
Principal Investigator: Mignon Loh, MD University of California, San Francisco
Principal Investigator: Paul Gaynon, MD Children's Hospital Los Angeles
Principal Investigator: Todd Cooper, MD Seattle Children's Hospital
Layout table for additonal information
Responsible Party: Epizyme, Inc.
ClinicalTrials.gov Identifier: NCT02141828    
Other Study ID Numbers: EPZ-5676-12-002
First Posted: May 20, 2014    Key Record Dates
Last Update Posted: May 8, 2020
Last Verified: May 2020
Keywords provided by Epizyme, Inc.:
Advanced hematologic malignancies
Phase 1b
MLL gene
Ambiguous lineage
Acute leukemias
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms by Histologic Type
Leukemia, Lymphoid
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases